Company
Headquarters: Copenhagen, Denmark
Employees: 3
kr514.0 Million
SEK as of July 1, 2024
US$48.4 Million
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $201.46 B |
| EssilorLuxottica SA | $144.43 B |
| Becton, Dickinson and Company | $55.63 B |
| HOYA Corp | $50.63 B |
| Alcon Inc. | $39.46 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. It develops FG001, which is in phase I/II for the treatment of high-grade glioma; and FG002 that allows surgeons to differentiate cancer from normal tissue during surgery through a novel urokinase-type plasminogen activator receptor targeted luminescent technology. It has an agreement with Linköping University Hospital for the development of FG001 that is in the phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was founded in 2018 and is based in Copenhagen, Denmark.
FluoGuide A/S has the following listings and related stock indices.
Stock: OMX: FLUO wb_incandescent
Stock: FSX: 96X wb_incandescent